Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
SEC semiannual reporting proposal divides firms
1+ day, 8+ hour ago (506+ words) At the center, weighing compliance savings for public companies against transparency concerns of the investment community. Furthermore, the SEC estimates that transitioning to semiannual filing could save companies approximately $200,000 annually in compliance costs, which is particularly compelling for smaller companies....
IP Strategy for Large Molecules, CAR-T, Biosimilars
1+ day, 12+ hour ago (445+ words) Natasha Daughtrey, partner at law firm Goodwin, stresses the need for a freedom to operate (FTO) analysis around the full manufacturing and development chain in these areas, as well as other insights for IP considerations. Natasha Daughtrey (ND): These three…...
Royalty Pharma buys cliramitug royalty stake
1+ day, 22+ hour ago (435+ words) Royalty Pharma has agreed to acquire a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug. Royalty Pharma will pay Neurimmune $125 million upfront, in return for a royalty of between 3% and 4% on worldwide net sales of cliramitug. A further $125 million in…...
Samsung Biologics buys PolyPeptide for $1.8bn
2+ day, 19+ hour ago (478+ words) The South Korean CDMO has proposed its largest-ever acquisition, targeting peptide specialist PolyPeptide in all-cash deal. Contract development manufacturing organization (CDMO) Samsung Biologics has announced an all-cash tender offer to acquire PolyPeptide Group AG for approximately CHF 1.46 billion ($1.8 billion). The…...
FDA pilot to supercharge US drug production
3+ day, 12+ hour ago (487+ words) The PreCheck pilot program brings together seven pharma companies in an attempt to build domestic drug supply chains. The US Food and Drug Administration (FDA) has announced the launch of its PreCheck Pilot program with the goal of investing in…...
Jupiter Neurosciences licenses MDMA drug ALA-002
3+ day, 12+ hour ago (244+ words) Jupiter Neurosciences enters psychedelic medicine with up to $100 million licensing deal for PharmAla's MDMA asset Jupiter Neurosciences has signed a licensing agreement with PharmAla Biotech Holdings for exclusive US rights to ALA-002. The deal marks Jupiter's expansion from a single-asset…...
Jeremy Levin's message to Europe
3+ day, 19+ hour ago (900+ words) As America's biotech ecosystem faces unprecedented structural challenges, industry expert Jeremy Levin sees a historic opportunity for Europe to claim leadership in life sciences innovation. The biotech industry stands at a crossroads. BioXconomy sat down with Levin ahead of BIO-Europe…...
Eyes on Asia: Insilico, Hansoh Pharma, Bora Pharmaceuticals
4+ day, 11+ hour ago (632+ words) BioXconomy presents the Asia biopharma and healthcare dealmaking highlights for the week ending July 19, 2026. Insilico Medicine has signed an “AI-empowered” drug discovery collaboration with China Medical System Holdings (CMS). The partnership targets a mass-market central nervous system (CNS) built around…...
Mission sells kidney drug to Dimerix for $292m
4+ day, 18+ hour ago (258+ words) Mission Therapeutics divests kidney asset MTX652 to Dimerix in deal worth up to $292 million to sharpen its focus on its Parkinson’s pipeline Dimerix will pay Mission $5 million upfront. An additional $47 million is tied to clinical development milestones. $40 million is available upon…...
Kalshi lets users bet on drug trial outcomes
5+ day, 3+ hour ago (415+ words) The prediction market exchange says wagering will boost transparency in pharma research and development. US “prediction market exchange,” Kalshi, will let people bet whether drugs will succeed in clinical trials and win regulatory approval. The gambling site announced it would…...